Pulmonary Arterial Hypertension (PAH)NCT07082933
Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and Diabetes
An observational study of Pulmonary Arterial Hypertension (PAH), run by Xijing Hospital.
Trial summary
This is a multicenter retrospective cohort study on pulmonary arterial hypertension. It is expected to collect data from no less than 5,000 patients to compare the long-term overall survival of patients with and without diabetes, and analysis the risk factors of the overall survival . Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Pulmonary Arterial Hypertension (PAH)
- What is being tested?
- Standard medical treatment
- How many people
- 5,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Aug 2025to 31 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with pulmonary hypertension
Who may be able to join
- Individuals aged 18 to 80 years with full capacity for civil conduct.
- Patients diagnosed with pulmonary hypertension by community-level and/or higher-level medical institutions.
Who cannot join
- Patients with malignant tumors.
- Other physical conditions judged by the researchers as making the patients ineligible to participate in the clinical study.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and diabetes-a Multicenter Retrospective Cohort Study
This is a multicenter retrospective cohort study on pulmonary arterial hypertension. It is expected to collect data from no less than 5,000 patients to compare the long-term overall survival of patients with and without diabetes, and analysis the risk factors of the overall survival .
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Being tested
- Standard medical treatment
- Keywords
- Pulmonary arterial hypertension, Diabetes, Mortality
- Medical subject headings
- Pulmonary Arterial Hypertension, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard medical treatmentOther
Standard medical treatment
| Study group | Role | What they receive |
|---|---|---|
| pulmonary arterial hypertension combined with diabetes | patients with pulmonary arterial hypertension and diabetes Receives: Other: Standard medical treatment | |
| pulmonary arterial hypertension without comorbid diabetes | pulmonary arterial hypertension without comorbid diabetes Receives: Other: Standard medical treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Time from diagnosis of pulmonary hypertension to death
Measured: 10 years
Secondary outcomes (1)
Pulmonary Artery Pressure(PAP)
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2025
- Study start1 Aug 2025 (estimated)
- Primary completion1 Aug 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pulmonary Arterial Hypertension (PAH)Studies of the same condition, open and under way.
- More trials run by Xijing HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xijing Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Yue Zhang, Doctor, Principal investigator, Department of Health Management, Xijing Hospital, Air Force Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07082933
- Sponsor's protocol ID
- KY-20252240
- Status last verified
- Jul 2025
- First submitted
- 16 Jul 2025
- Last updated
- 24 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-term Survival and Influencing Factors of Patients With Pulmonary Arterial Hypertension and diabetes-a Multicenter Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT07082933
- Acronym / sponsor ID
- KY-20252240
- Conditions
- Pulmonary Arterial Hypertension (PAH)
- Keywords
- Pulmonary arterial hypertension, Diabetes, Mortality
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- Xijing HospitalUniversity, hospital or other
- Study start
- 1 Aug 2025 (estimated)
- Primary completion
- 1 Aug 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 24 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multicenter retrospective cohort study on pulmonary arterial hypertension. It is expected to collect data from no less than 5,000 patients to compare the long-term overall survival of patients with and without diabetes, and analysis the risk factors of the overall survival .
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| pulmonary arterial hypertension combined with diabetes | – | Other: Standard medical treatmentpatients with pulmonary arterial hypertension and diabetes |
| pulmonary arterial hypertension without comorbid diabetes | – | Other: Standard medical treatmentpulmonary arterial hypertension without comorbid diabetes |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with pulmonary hypertension
Key inclusion criteria (2 listed)
- Individuals aged 18 to 80 years with full capacity for civil conduct.
- Patients diagnosed with pulmonary hypertension by community-level and/or higher-level medical institutions.
Key exclusion criteria (2 listed)
- Patients with malignant tumors.
- Other physical conditions judged by the researchers as making the patients ineligible to participate in the clinical study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard medical treatmentStandard medical treatment | Other | pulmonary arterial hypertension combined with diabetes, pulmonary arterial hypertension without comorbid diabetes |
Primary outcome
Overall Survival
Time frame: 10 years
Time from diagnosis of pulmonary hypertension to death
1 secondary outcome
Pulmonary Artery Pressure(PAP)
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for Pulmonary Arterial Hypertension (PAH)
Active, not recruitingPhase 1
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Pulmonary Arterial Hypertension
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
RecruitingPhase 4
Sotatercept in Pulmonary Arterial Hypertension
Pulmonary Artery Hypertension
Not yet recruiting
Home-based Inspiratory Muscle Training in Pulmonary Hypertension
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Yue Zhang, Doctor principal investigator
Department of Health Management, Xijing Hospital, Air Force Medical University
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Arterial Hypertension (PAH), run by Xijing Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yue Zhang, Doctor (0086+13022957751, zhangy718@foxmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025.